Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome
We identified a new stakeholder, PAPPA-2, known to modulate IGF bioavailability, as playing a possible role in GLP-2 mechanism of action in human with SBS. We showed by association the existence of a greater spontaneous intestinal adaptation in SBS patients with a colon in continuity that could reduce sensitivity to teduglutide. Additionally, we suggest that initial PAPPA2 expression could serve as a predictive biomarker for teduglutide efficacy.
Authors
- André Bado (ORCID: https://orcid.org/0000-0002-8007-1460)
- Johanne Le Beyec (ORCID: https://orcid.org/0000-0002-5647-2002)
- Rémy Nicolle (ORCID: https://orcid.org/0000-0001-8084-1173)
- Francisca Joly (ORCID: https://orcid.org/0000-0002-9341-7133)
- Nicolas Poté (ORCID: https://orcid.org/0000-0001-7695-7317)
- Jérôme Cros (ORCID: https://orcid.org/0000-0002-4935-3865)
- Dominique Cazals‐Hatem (ORCID: https://orcid.org/0000-0002-7180-6242)
- Maude Le Gall (ORCID: https://orcid.org/0000-0002-5372-4585)
- Brune de Dreuille (ORCID: https://orcid.org/0009-0008-9543-0500)
- Anaïs Chassac (ORCID: https://orcid.org/0000-0001-7964-501X)
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Hôpital Beaujon (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre de Recherche sur l'Inflammation (FR)
- Hôpital Bichat-Claude-Bernard (FR)
Publication Details
- Journal
- Clinical Nutrition
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1016/j.clnu.2025.05.006
- Citations
- 3
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 3.36
Funders
- Société Francophone Nutrition Clinique et Métabolisme